OTS Member Highlight – Masad Damha, PhD
For Masad Damha, falling in love with science was easy. Growing up in Managua, Nicaragua, his high school teachers encouraged scientific exploration, curiosity, and experimentation, such as processing vegetable oil into soap, producing hydrogen and oxygen from water via electrolysis, and determining the gravitational force constant using a pendulum. ...
Targeting DNA Mismatch Repair as a Potential Therapeutic Strategy for Huntington’s Disease
Huntington's disease (HD) is a devastating and fatal neurodegenerative disorder affecting movement, thinking, and behavior. In the United States alone, there are approximately 40,000 people with symptomatic Huntington's disease, and more than 200,000 are at risk of inheriting it. The fatal disease often leaves a devastating family legacy, as ...
FDA Approval of Vutrisiran Brings New Treatment for ATTR-CM
When Sean Riley started getting numbness in his hands, he saw a local surgeon who performed carpal tunnel surgery on both his wrists. At the time, he didn't think much of his symptoms, knowing carpal tunnel was common, he attributed his symptoms to the typing he occasionally did. Then, ...
OTS Member Highlight – David Corey, PhD
Former Oligonucleotide Therapeutics Society (OTS) President David Corey grew up being inspired by his father's love of science, noting that his father was not only good at what he did but he also enjoyed it. "I never measured myself against him because I knew I could not expect to ...
NanoCas: A Newly Identified Compact Nuclease May Expand CRISPR’s Reach
The revolutionary CRISPR-Cas system has proven to be a precise method for genome editing, showing great promise in tackling genetic disorders. However, clinical trials for CRISPR-based treatments have faced delivery challenges due to the large size of the editing system. In the quest to overcome these limitations, researchers recently ...
OTS Member Highlight – Holly Kordasiewicz, PhD
Holly Kordasiewicz was a curious, chatty child with a penchant for asking questions. At dinner, conversations were often about the fascinating things her mom, a registered nurse, learned at work, sparking Kordasiewicz's interest in medicine and biology. As her grandparents aged, and she witnessed neurodegenerative diseases gradually and relentlessly ...
OTS Member Highlight – Dr. Annemieke Aartsma-Rus
Growing up the oldest of four children in Leiden, Netherlands, Dr. Annemieke Aartsma-Rus became fascinated with medical research and genetics as a teenager. While her father's work as a physician made her realize she didn't want to be a doctor, it did teach her that there were numerous diseases ...
Targeting the Kidney: The Promise of RNA-Based Therapeutics
When Yessenia Gutierrez was just nine years old, her kidneys failed; at 10 years old, she received her first kidney transplant. Gutierrez was born with polycystic kidney disease (PKD), a genetic condition that makes fluid-filled cysts grow on the kidney and can lead to kidney failure. Growing up, Gutierrez ...
2024 FDA Approvals: A Wave of Innovation in Treating Serious Diseases
In 2024, the Food and Drug Administration Center for Drug Evaluation (CDER) approved 50 new small molecules, biologics, and oligonucleotide therapies (1). The approvals — the second largest in 30 years — include an oligonucleotide therapy for blood cancer, an antisense oligonucleotide shown to significantly drop triglyceride levels, and ...
Transporting Therapeutics: A Novel Approach to Deliver ASOs to the Brain
Antisense oligonucleotide (ASO) therapies, which bind to RNA and modify protein expression, are promising drugs for treating neurological conditions. However, their inability to cross the blood-brain barrier (BBB) sometimes makes injection directly into the cerebral spinal fluid (via intrathecal injection) necessary, which is not without its risks or drawbacks ...
OTS Member Highlight – Masad Damha, PhD
For Masad Damha, falling in love with science was easy. Growing up in Managua, Nicaragua, his high school teachers encouraged scientific exploration, curiosity, and experimentation, such as processing vegetable ...
Targeting DNA Mismatch Repair as a Potential Therapeutic Strategy for Huntington’s Disease
Huntington's disease (HD) is a devastating and fatal neurodegenerative disorder affecting movement, thinking, and behavior. In the United States alone, there are approximately 40,000 people with symptomatic Huntington's disease, ...
FDA Approval of Vutrisiran Brings New Treatment for ATTR-CM
When Sean Riley started getting numbness in his hands, he saw a local surgeon who performed carpal tunnel surgery on both his wrists. At the time, he didn't think ...
OTS Member Highlight – David Corey, PhD
Former Oligonucleotide Therapeutics Society (OTS) President David Corey grew up being inspired by his father's love of science, noting that his father was not only good at what he ...
NanoCas: A Newly Identified Compact Nuclease May Expand CRISPR’s Reach
The revolutionary CRISPR-Cas system has proven to be a precise method for genome editing, showing great promise in tackling genetic disorders. However, clinical trials for CRISPR-based treatments have faced ...
OTS Member Highlight – Holly Kordasiewicz, PhD
Holly Kordasiewicz was a curious, chatty child with a penchant for asking questions. At dinner, conversations were often about the fascinating things her mom, a registered nurse, learned at ...
OTS Member Highlight – Dr. Annemieke Aartsma-Rus
Growing up the oldest of four children in Leiden, Netherlands, Dr. Annemieke Aartsma-Rus became fascinated with medical research and genetics as a teenager. While her father's work as a ...
Targeting the Kidney: The Promise of RNA-Based Therapeutics
When Yessenia Gutierrez was just nine years old, her kidneys failed; at 10 years old, she received her first kidney transplant. Gutierrez was born with polycystic kidney disease (PKD), ...
2024 FDA Approvals: A Wave of Innovation in Treating Serious Diseases
In 2024, the Food and Drug Administration Center for Drug Evaluation (CDER) approved 50 new small molecules, biologics, and oligonucleotide therapies (1). The approvals — the second largest in ...
Transporting Therapeutics: A Novel Approach to Deliver ASOs to the Brain
Antisense oligonucleotide (ASO) therapies, which bind to RNA and modify protein expression, are promising drugs for treating neurological conditions. However, their inability to cross the blood-brain barrier (BBB) sometimes ...




















